Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Cash on Hand
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Comment by Marky1on Jan 10, 2021 2:46pm
180 Views
Post# 32263656

RE:RE:RE:RE:RE:RE:RE:RE:Cash on Hand

RE:RE:RE:RE:RE:RE:RE:RE:Cash on Hand

I respectfully disagree with you Magic...I don't believe that ATE is dead money for the next 6 months.

With the signing of Haut and Stauffer...and taking on Stern IR...I think negotiations are well underway for a Partnership ( likely ) or takeover ( doubtful)

I feel that starting tomorrow, we will be headed upwards....We just need catalysts to start the game , If Repare can be a. 2B$ CDN company with a preclinical drug, a drug with some obscure science..
( synthetic Lethality approach)  whatever that means??

We have  a drug entering P3 testing with a clear and focused pathway...an amazing new technology behind us

At a 2B$ MC USD....that's puts us at 50$ a share

Thank you
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities